{"id":"W4403455365","doi":"10.1177/17562848241290636","title":"Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"Szent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem; National Research, Development and Innovation Office; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Bristol-Myers Squibb; Eli Lilly and Company; Szegedi Tudományegyetem; Emberi Eroforrások Minisztériuma; Celltrion; Teva Pharmaceutical Industries; Gilead Sciences; Amgen; Pfizer; Horizon 2020 Framework Programme","keywords":"Vedolizumab; Medicine; Inflammatory bowel disease; Internal medicine; Gastroenterology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00250149,0.0002535313,0.000616516,0.0005393804,0.0003759067,0.000626863,0.0002705129,0.0005008333,0.001181573],"category_scores_gemma":[0.005757282,0.0001314716,0.001152545,0.0005653207,0.0002405158,0.0005181652,0.0004791136,0.0007324332,0.0001492777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004425394,"about_ca_system_score_gemma":0.000276484,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008113331,"about_ca_topic_score_gemma":0.0007568907,"domain_scores_codex":[0.9986739,0.0004912329,0.000176396,0.0001643547,0.0002953334,0.0001987032],"domain_scores_gemma":[0.9916401,0.001617139,0.005236461,0.000245636,0.0004611363,0.0007995396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00746893,0.0005552504,0.9754291,0.00009182822,0.0002957331,0.0001773697,0.0001813278,0.0001734597,0.0004683975,0.00001314802,0.00009642082,0.01504914],"study_design_scores_gemma":[0.0001028641,0.002903005,0.9959744,0.00001438822,0.0001380374,0.0002098703,0.0000917306,0.0002342633,0.0001560859,0.0000124131,0.0001546018,0.000008288201],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991755,0.0004428791,0.00003463588,0.00002243532,0.000003989937,0.0000189699,0.0000853888,0.000001544815,0.0002145947],"genre_scores_gemma":[0.9994946,0.0001092171,0.00003175016,0.00002156822,0.000009983469,0.00001576647,0.0002288522,8.412228e-7,0.00008750153],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00250149,"threshold_uncertainty_score":0.01322931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005912891383417481,"score_gpt":0.2692807805838435,"score_spread":0.263367889200426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}